The apolipoprotein E ε4 allele and outcome in cerebrovascular disease

Stroke

Volumn 29, Issue 9, 1998, Pages 1882-1887

  McCarron, M O ^a   Muir, K W ^a   Weir, C J ^b   Dyker, A G ^b   Bone, I ^a   Nicoll, James A R ^a   Lees, K R ^b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b Gardiner Institute   (United Kingdom)

Author keywords

Apolipoproteins; Stroke outcome

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; AGED; ALLELE; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; SURVIVAL; TRANSIENT ISCHEMIC ATTACK; BRAIN ISCHEMIA; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR DISORDERS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031595697     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.9.1882     Document Type: Article

References (47)

1. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994;17:525-530.
2. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance MA, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993; 90:1977-1981.
3. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
4. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation. 1995;91:265-269.
5. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 1993;24:661-664.
6. Pedro-Botet J, Senti M, Xavier N, Rubies-Prat J, Roquer J, D'Olhaberriague L, Olive J. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein (a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23: 1556-1562.
7. Kessler C, Spitzer C, Stauske D, Mende S, Stadlmuller J, Walther R, Rettig R. The apolipoprotein E and β-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large vessel disease. Arterioscler Thromb Vasc Biol. 1997;17:2880-2884.
8. Mahieux F, Bailleul S, Fenelon G, Couderc R, Laruelle P, Guillard A. Prevalence of apolipoprotein E phenotypes in patients with acute ischemic stroke. Stroke. 1990;21(suppl I):I-115.
9. Coria F, Rubio I, Nunez E, Santa Engracia N, Bayon C, Cuadrado N. Apolipoprotein E variants in ischemic stroke. Stroke. 1995;26: 2375-2376. Letter.
10. Basun H, Corder EH, Guo Z, Lannfelt L, Corder LS, Manton KG, Winblad B, Viitanen M. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke. 1996;27: 1310-1315.
11. Hachinski V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, Spence D, Doig G, Wolfe BMJ. Lipids and stroke. Arch Neurol. 1996; 53:303-308.
12. Kuusisto J, Mykkanen L, Kervinen K, Kesaniemi A, Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler Thromb Vasc Biol. 1995;15:1280-1286.
13. Ferrucci L, Guralnik JM, Pahor M, Harris T, Corti MC, Hyman BT, Wallace RB, Havlik RJ. Apolipoprotein E ∈2 allele and risk of stroke in the older population. Stroke. 1997;28:2410-2416.
14. Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla T, Hyman BT. Apolipoprotein E ∈4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254-259.
15. Nicoll JAR, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, Stewart J, Vinters HV. High frequency of apolipoprotein E ∈2 allele in haemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;41: 716-721.
16. Kalaria RN, Premkumar DRD. Apolipoprotein E genotype and cerebral amyloid angiopathy. Lancet. 1995;346:1424. Letter.
17. Greenberg SM, Hyman BT. Cerebral amyloid angiopathy and apolipoprotein E: bad news for the good allele? Ann Neurol. 1997;41: 701-702.
18. McCarron MO, Nicoll JAR. High frequency of apolipoprotein E ∈2 allele is specific for patients with cerebral amyloid angiopathy-related hemorrhage. Neurosci Lett. 1998;247:45-48.
19. Teasdale GM, Nicoll JAR, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997; 350:1069-1071.
20. Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S. Apolipoprotein E ∈4 associated with chronic traumatic brain injury in boxing. JAMA. 1997;278:136-140.
21. Sorbi S, Nacmias B, Piacentini S, Repice A, Latorraca S, Forleo P, Amaducci L. ApoE as a prognostic factor for post-traumatic coma. Nature Med. 1995;1:852. Letter.
22. Alberts MJ, Graffagnino C, McClenny C, DeLong D, Strittmatter W, Saunders AM, Roses AD. ApoE genotype and survival from intracerebral hemorrhage. Lancet. 1995;346:575. Letter.
23. Bamford JM, Sandercock PAG, Dennis MS, Burn J, Warlow CP. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
24. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;41:479-486.
25. Kendrick S, Clarke J. The Scottish record linkage system. Health Bull (Edinb). 1993;51:1-15.
26. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JWK, Wapshaw JA. Mortality in patients of the Glasgow blood pressure clinic. J Hypertens. 1986;4:141-156.
27. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol. 1995;48:1441-1452.
28. Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: retrospective study. BMJ. 1997;314:1584-1588.
29. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ. 1997;314:1303-1306.
30. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
31. Kay R, Sing Wong K, Yu LY, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333: 1588-1593.
32. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34: 187-220.
33. Cumming AM, Robertson F. Polymorphism at the apo E locus in relation to risk of coronary disease. Clin Genet. 1984;25:310-313.
34. Greenberg SM, Briggs M, Hyman BT, Kokons GJ, Takis C, Kanter DS, Kase CS, Pessin MS. Apolipoprotein E ∈4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke. 1996;27:1333-1337.
35. Case records of the Massachusetts General Hospital. N Engl J Med. 1996;335:189-196.
36. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18:311-324.
37. Muir KW, Weir CJ, Murray GD, Povey C, Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27:1817-1820.
38. Horsburgh K, Nicoll JAR. Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischemia in the rat. Neuropathol Appl Neurobiol. 1996;22:342-349.
39. Horsburgh K, Fitxpatrick M, Nilsen M, Nicoll JAR. Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural hematoma in rat. Brain Res. 1997;763:103-110.
40. Laskowitz DT, Sheng H, Bart RD, Joyner KA, Roses AD, Warner DS. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab. 1997;17:753-758.
41. Masliah E, Mallory M, Nianfeng G, Alford M, Veinbergs I, Roses AD. Neurodegeneralion in the central nervous system of apo E-deficient mice. Exp Neurol. 1995;136:107-122.
42. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264:850-852.
43. Puttfarcken PS, Manelli AM, Falduto MT, Getz GS, LaDu MJ. Effect of apolipoprotein E on neurite outgrowth and β-amyloid-induced toxicity in developing rat primary hippocampal cultures. J Neurochem. 1997;68: 760-769.
44. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects of cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet. 1996;14:55-61.
45. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996; 380:168-171.
46. Laskowitz DT, Goel S, Bennett ER, Mathew WD. Apolipoprotein E suppresses glial secretion of TNFα. J Neuroimmunol. 1997;76:70-74.
47. Kervinen K, Savolainen MJ, Salokannel J, Hynninen A, Heikkinen J, Ehnholm C, Koistinen MJ, Kesaniemi YA, Apolipoprotein E, and B polymorphisms: longevity factors assessed in nonagenarians. Atherosclerosis. 1994;105:89-95.